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Abstract
Background: Minocycline is a tetracycline antibiotic that has been proposed as a potential conjunctive therapy for HIV-1
associated cognitive disorders. Precise mechanism(s) of minocycline’s functions are not well defined.
Methods: Fourteen rhesus macaques were SIV infected and neuronal metabolites measured by proton magnetic resonance
spectroscopy (
1H MRS). Seven received minocycline (4 mg/kg) daily starting at day 28 post-infection (pi). Monocyte
expansion and activation were assessed by flow cytometry, cell traffic to lymph nodes, CD16 regulation, viral replication,
and cytokine production were studied.
Results: Minocycline treatment decreased plasma virus and pro-inflammatory CD14+CD16+ and CD14
loCD16+ monocytes,
and reduced their expression of CD11b, CD163, CD64, CCR2 and HLA-DR. There was reduced recruitment of monocyte/
macrophages and productively infected cells in axillary lymph nodes. There was an inverse correlation between brain NAA/
Cr (neuronal injury) and circulating CD14+CD16+ and CD14
loCD16+ monocytes. Minocycline treatment in vitro reduced SIV
replication CD16 expression on activated CD14+CD16+ monocytes, and IL-6 production by monocytes following LPS
stimulation.
Conclusion: Neuroprotective effects of minocycline are due in part to reduction of activated monocytes, monocyte traffic.
Mechanisms for these effects include CD16 regulation, reduced viral replication, and inhibited immune activation.
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Introduction
Human immunodeficiency virus (HIV) infection of the central
nervous system (CNS) can result in cognitive impairment,
behavioral deficits, and motor dysfunction. With the use of anti-
retroviral therapy (ART) the incidence of HIV-associated
neurological disease has declined [1]. While ART prolongs health
and longevity of HIV-infected individuals, the majority of anti-
retroviral drugs have poor CNS penetration. As a result, the
prevalence of neurologic complications in HIV-infected patients
continues to rise [2]. Factors mediating inflammatory responses
outside the CNS likely play critical roles in CNS dysfunction.
Monocyte/macrophage traffic likely plays a significant role in
driving CNS neuropathogenesis [3–6].
Monocyte traffic across the blood-brain barrier (BBB) occurs at
a basal level that increases with immune activation [7]. Such traffic
likely serves as a primary route of viral entry into the CNS [8] and
regulates the accumulation of macrophages in encephalitic lesions,
which are the histopathological correlate of HIV-associated
neurocognitive disorders (HAND). The majority of monocytes
express the lipopolysaccharide (LPS) receptor CD14, while only
approximately ten percent also express the FccIII receptor CD16
under normal conditions [9], [10]. Following viral infection, with
inflammation, the number of monocytes as well as the percentages
of activated monocyte subsets increase, resulting in increased
traffic to and accumulation within tissues including the brain [11],
[12]. Once activated, CD14+CD16+ and CD14
loCD16+ mono-
cytes express high levels of pro-inflammatory cytokines that are
linked to the development of HAND and simian immunodefi-
ciency virus encephalitis (SIVE) [12], [13]. With HIV and SIV
infection, the number of CD14+CD16+ monocytes increases [14],
[15]. HIV and SIV DNA and RNA are found in both
CD14+CD162 and CD14+CD16+ monocyte subsets in acute
infection and AIDS. Viral DNA is consistently found in
CD14+CD16+ monocytes throughout disease [16], [17]. We have
shown that perivascular macrophages are repopulated from bone
marrow in normal rhesus macaques [18] and are a primary cell
productively HIV and SIV infected in the CNS [19], [20].
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CNS perivascular macrophage; both express CD14, CD16, and
CD163. Thus, it is likely that subsets of CD14+CD16+CD163+
monocytes, some of which are infected, repopulate CNS
perivascular macrophages [6], [21]. Thus, therapies targeting
monocyte/macrophages outside the CNS can potentially affect
neuronal injury.
Minocycline, a lipid soluble tetracycline antibiotic that has
putative effects on immune system cells, fortuitously can also
effectively cross the blood brain barrier (BBB) into the CNS
parenchyma [22]. Several studies established that minocycline
possesses anti-inflammatory and possibly direct neuroprotective
properties independent of its antimicrobial effects [23], [24].
Animal studies indicate minocycline inhibits the production of
immune activators by macrophages, microglia [25–28], and
neurons [26–28]. Minocycline inhibits activation, proliferation,
and viral replication of microglia, macrophages, and lymphocytes
in vitro [25,28–30]. In SIV-infected pigtailed macaques, minocy-
cline reduced plasma virus, the pro-inflammatory monocyte
chemoattractant protein 1 (MCP-1)/CCL2, and viral DNA in
the CNS [28]. Whether decreased monocyte/macrophage activa-
tion by minocycline also plays a neuroprotective role via such
mechanisms is not well-defined. To date studies correlating
neuronal injury simultaneously with viral infection and mono-
cyte/macrophage activation have not been done.
Here, we report the effects of minocycline on monocyte/
macrophage numbers and activation, and neuronal injury in a
pathogenesis study. We used a CD8+ T lymphocyte depletion
model of SIV infection in rhesus macaques, which results in rapid
progression to AIDS (3–4 months) with a high incidence of SIVE
[31]. Using this model and magnetic resonance (MR) spectroscopy
we found that minocycline treatment resulted in stable N-
acetylaspartate to Creatine (NAA/Cr) levels in the brain
(representing neuronal protection) compared to non-treated
animals, which continued to decline (consistent with neuronal
injury) [32]. In the current study, using the same cohort and three
additional control non-minocycline treated animals, we report
minocycline treatment reduced activation of monocytes that
inversely correlated with neuronal injury, reduced the accumula-
tion of monocyte/macrophages in lymph nodes of treated animals,
and inhibited the expression of CCR2, CD163, CD11b, and
CD64 on monocytes. These results suggest that minocycline, by
down-regulating CD16 and viral replication, inhibiting monocyte
activation and immune cell traffic, is neuroprotective.
Results
Fourteen animals were SIV-infected and treated with an anti-
CD8+ T lymphocyte antibody (cM-T807), administered at 6, 8,
and 12 days post infection (dpi). Three were transiently CD8+
lymphocyte depleted (#21 dpi), while the remaining eleven were
persistently CD8+ lymphocyte depleted (.28 dpi) (Table 1). Over
the course of the study, there were no significant differences in the
plasma viral load or numbers of monocyte subsets between the
transiently and persistently CD8 lymphocyte depleted animals. We
have previously shown that persistent CD8+ lymphocyte depletion
results in rapid AIDS (3–4 months) with a high incidence of SIVE
(.85%) [33], [34]. Minocycline (4 mg/kg/day) was initiated
28 dpi given daily as we previously reported [32]. Animals were
sacrificed with the development of AIDS or at a previously
determined timed sacrifice. Plasma SIV RNA peaked at 10
8 copy
eq./mL by 12 dpi. Plasma virus decreased by approximately one
log after 7 days of minocycline treatment and remained at that
level until sacrifice (Table 1).
Flow cytometric analyses were completed by employing a gating
strategy where peripheral blood monocytes were initially identified
according to forward scatter and side scatter properties (Figure 1A)
[10], [34]. A small population of CD14-negative, HLA-DR-
negative cells, likely representing lymphocytes or dendritic cells,
was excluded by gating on all CD14+ HLA-DR+ cells. Within this
gate, monocyte subsets were defined by expression of CD14 versus
CD16. The absolute numbers of classical CD14+CD162
monocytes were comparable between groups prior to and after
minocycline treatment (Figure 1B). The absolute number of
activated CD14+CD16+ (Figure 1C) and CD14
loCD16+
(Figure 1D) monocytes increased in the untreated group but were
significantly reduced in minocycline treated animals at all time
points.
The median fluorescence intensity (MFI) of CD11b, CD163,
CCR2, CD64 and HLA-DR on monocyte subsets prior to
minocycline treatment (day 27) and terminally was examined
(Table 2). Day 27 was selected because it was a time point
immediately preceding minocycline treatment and is a point of
peak monocyte activation. All markers studied on monocyte
subsets from SIV-infected macaques without minocycline treat-
ment were increased one to four-fold at sacrifice compared to day
27 pi. In contrast, there was a two to seven-fold decrease in MFI
expression of CD11b, CD163, CCR2, CD64, and HLA-DR
between minocycline treated and untreated animals terminally.
Interestingly, the MFI of these markers on monocytes from
minocycline treated animals terminally was very similar to the
values found the prior to treatment indicating that minocycline
treatment reduces monocyte/macrophage activation in vivo.
Additionally, the MFI for HLA-DR decreased on all monocyte
subsets two-fold less than the pretreatment values (Table 2). Thus,
minocycline treatment reduces the expression of several markers
critical for monocyte traffic and function at late stage of infection,
and in the case of HLA-DR is reduced below that found prior to
minocycline treatment.
Next, we examined possible correlations between longitudinal
changes in monocyte numbers and the ratio of N-acetylaspartate to
Creatine (NAA/Cr) in different brain regions of the same animals
with and without minocycline treatment. The NAA/Cr ratio in the
frontal cortex, parietal cortex, white matter, and basal ganglia was
previously determined and reported [32] where decreases were
found in all SIV-infected animals prior to minocycline treatment
(dpi 27) [32]. At four weeks pi, following minocycline treatment,
NAA/Cr in treated animals was stabilized, whereas untreated
animals had a continued decline [32]. Linear regression analyses
revealed a highly significant relationship between the absolute
number of pro-inflammatory CD14+CD16+ and CD14
loCD16+
monocytes and NAA/Cr (in all brain regions). The relationship
between monocyte subsets and NAA/Cr in the frontal cortex
(CD14+CD16+:r
2=0.59, p=0.0004; CD14
loCD16+:r
2=0.45,
p=0.04) representative of the other brain regions is illustrated in
Figure 2. In the parietal cortex we found: CD14+CD16+:r
2=0.67,
p=0.0003; CD14
loCD16+:r
2=0.55, p=0.0007. In the basal
ganglia we found: CD14+CD16+:r
2=0.53, p=0.039;
CD14
loCD16+:r
2=0.26, p=0.36. In the white matter:
CD14+CD16+:r
2=0.52, p=0.0012; CD14
loCD16+:r
2=0.50,
p=0.0006. We only found a significant correlation between
CD14+CD162 monocytes and NAA/Cr in the parietal cortex
(CD14+CD162:r
2=0.36, p=0.02). Correlations between
CD14+CD162 monocytes in other brain regions were not
significant (data not shown). The inverse relationship between
activated CD14+CD16+ and CD14
loCD16+ monocytes with
NAA/Cr coupled with the observation that minocycline treatment
reduces the number of activated monocytes, supports the notion
Neuronal Protection by Minocycline
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of activated monocytes.
We previously reported that none of the minocycline treated
animals developed SIVE (defined as the accumulation of
monocyte/macrophages, virally infected cells, and multi-nucleated
giant cells) [32]. Examining axillary lymph nodes we found a
statistically significant reduction in the relative numbers of resident
mature CD68+ macrophages (Figure 3A–B, Figure 4A;
p=0.0023), recently recruited MAC387+ monocytes/macrophag-
es (Figure 3C–D, Figure 4B; p=0.0033), and productively infected
SIV p28+ cells (Figure 3E–F, Figure 4C; p=0.0070) with
minocycline. This finding is consistent with reduced traffic and
activation of monocyte/macrophages, as well as productive
infection in lymph nodes (Figure 4A–C) similar to the decreased
infection we reported in the CNS [32].
In vitro experiments were used to determine the effect of
minocycline on monocyte CD16+ with viral infection. CD16
expression on monocyte/macrophages was reduced follo-
wing10 mM minocycline for 24 hours, and was significantly
reduced using 20 mM minocycline for 24 hours (Figure 5). By
72 hours of treatment, CD16 expression was significantly
decreased on minocycline treated cells at both concentrations
(Figure 5A–B) while CD14 expression was unchanged (data not
shown). These data suggest that by down-regulating CD16,
minocycline treatment may prevent differentiation, activation, or
both on monocyte/macrophages. Such inhibition of monocyte/
macrophage activation or differentiation in vivo may result in
decreased replication or abundance of CD14+CD16+ target cells
for HIV and SIV. In addition, 20 mM minocycline in vitro
significantly reduced SIV replication by monocyte/macrophages
96 hours post-infection (Figure 5C). Whether the inhibition of
viral replication in monocytes in vitro is due to a block of viral entry
or post entry event requires further study. Minocycline did not
result in monocyte cell death as measured by LIVE/DEAD cell
staining (data not shown). We note that in vitro doses of
minocycline used here (10 mM and 20 mM) are similar to those
found in serum of minocycline treated humans [35]. Collectively,
these data indicate that both CD16 expression and viral
replication are reduced with minocycline treatment, consistent
with the effects of minocycline observed in vivo.
Further in vitro experiments were completed to determine the
effect of minocycline on pro-inflammatory cytokine production in
response to LPS stimulation (Figure 6). The percentage of CD14+
monocytes producing IL-6 after 3 hours of culture without
stimulation was significantly lower with 10 mM( p=0.04) and
20 mM( p=0.009) minocycline treatment. Following 3 hours
of stimulation with 10 ng/mL LPS, the percent of IL-6 produc-
ing monocytes was significantly lower with 20 mM than with
10 mM minocycline (p=0.016). With a higher concentration of
100 ng/mL LPS, minocycline treatment at both 10 mM( p=0.058)
and 20 mM( p=0.03) doses significantly inhibited IL-6 cytokine
secretion in CD14+ monocytes (Figure 6). TNF production in
response to LPS stimulation was also examined, however there
was no significant difference between untreated and minocycline
treated monocytes following 10 ng/mL or 100 ng/mL LPS (data
not shown).
Discussion
Here, we demonstrate a correlation between expansion of
activated monocytes and neuronal protection with minocycline
in a rapid model of SIV-neuropathogenesis. We found decreased
traffic of monocyte/macrophages to lymph nodes in minocycline
treated animals, and in vitro evidence of a down-regulation of
CD16 expression, a marked decrease in viral replication, as well
as inhibition of IL-6 production following LPS stimulation. In
minocycline treated animals we did not observe an expansion of
CD14+CD16+ and CD14
loCD16+ monocytes that was observed
in untreated animals with AIDS. These data parallel our
previous results showing a direct relationship between the
expansion of activated monocyte populations and decreased
NAA/Cr [32].
Table 1. SIV-infected, CD8+ T Lymphocyte depleted animals used in this study.
Animal no. Minocycline
Length of
infection (days)
CD8+ lymphocyte
depletion
a
Terminal plasma viral
load (copy eq. /mL)
b
74 – 05 None 56 Persistently depleted 5.6610
7
79 - 05 None 42* Persistently depleted 6.3610
7
156 - 04 None 62 Persistently depleted 3.6610
8
346 - 04 None 62 Persistently depleted 6.2610
8
307 - 05 None 43* Persistently depleted 6.5610
7
118 - 07 None 57 Persistently depleted 1.8610
8
121 - 07 None 57 Persistently depleted 2.2610
8
94 - 04 Started 28 dpi 60 Persistently depleted 9.0610
6
35 - 07 Started 28 dpi 62 Persistently depleted 8.0610
7
150 - 04 Started 28 dpi 60 Persistently depleted 8.3610
7
150 - 05 Started 28 dpi 55 Persistently depleted 6.3610
7
48 - 07 Started 28 dpi 62 Transiently depleted 4.3610
6
227 - 04 Started 28 dpi 60 Transiently depleted 8.9610
6
258 - 04 Started 28 dpi 62 Transiently depleted 2.7610
7
Note.-dpi=days post infection.
*Untreated animals time-sacrificed at 6 weeks pi; all other animals sacrificed at 8 weeks pi.
aTransiently CD8+ lymphocyte depleted (#21 dpi), persistently CD8+ lymphocyte depleted (.28 dpi).
bViral RNA quantitiated using RT PCR and are results of duplicate measurements.
doi:10.1371/journal.pone.0018688.t001
Neuronal Protection by Minocycline
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pathological changes, neuronal injury as measured by decreased
NAA/Cr was detected by two weeks pi coincident with an
elevation in activated CD14+CD16+ monocytes. Virus enters the
CNS consistently by two weeks pi likely through trafficking of
monocytes into the brain [34], [36]. This appears to be sufficient
for the induction of neuronal damage. We observed a decrease in
the absolute number of monocytes with minocycline treatment
with no further CNS damage, supporting the notion that
monocyte expansion is required to drive disease.
In previous work, we observed a bi-phasic increase in the
number and relative percentage of activated monocytes with the
second peak occurring with peripheral immune system dysfunction
and a steep decline in NAA/Cr ratios [33]. The levels of
circulating monocytes in untreated animals followed this well-
described pattern of biphasic monocyte expansion with the
development of AIDS, but this second peak was not seen in the
minocycline treated animals. In fact there was a decrease in the
number of such cells as well as the level of immune activation and
accessory molecules on total monocytes.
The neuroprotective effects of minocycline confirm previous
observations by Zink et al. [28] who found decreased activation of
tissue macrophages, CNS viral load, and severity of CNS disease
with minocycline treatment in SIV-infected pigtail macaques. Our
results extend these findings by demonstrating that the effects of
minocycline are directly correlated with reduced number of
activated monocyte/macrophage and decreased activation mar-
kers on these pro-inflammatory cells. Zink and colleagues also
examined alterations in the potent monocyte chemoattractant
protein (MCP-1) throughout infection and with minocycline
treatment. MCP-1 concentration in CSF followed a biphasic
pattern with elevations during acute infection that declined after
10–14 dpi and again increased after four weeks of infection. In
macaques treated with minocycline during chronic infection, the
second peak in MCP-1 levels in CSF was not observed [37]. This
is very similar to our observations that minocycline treated
macaques did not have a second wave of activated CD14+CD16+
and CD14
loCD16+ monocytes. In addition, although expression
of the MCP-1 receptor CCR2 was also significantly increased on
the pro-inflammatory monocytes of untreated animals in our
study, we found CCR2 levels remained unchanged on activated
monocytes from minocycline treated animals, suggesting that
minocycline may disrupt the recruitment and trafficking of highly
activated monocytes into the CNS. This was further supported by
our findings of reduced recruitment, viral replication, and
activation of macrophages in the lymph nodes of minocycline
treated animals.
Classically activated CD14+CD162 monocytes express CD64
(FccRI), CCR2, low levels of HLA-DR, and release cytokines such
as IFN-b and IL-10 [38]. In response to inflammation and viral
infection, there is an expansion of more mature CD14+CD16+
and CD14
loCD16+ monocyte populations first with acute
infection and again with the development of AIDS, when these
cells can represent up to 40% of the total circulating monocyte
population [10], [33]. These monocytes express high levels of
CD11b, CD163, and HLA-DR and release high levels of pro-
inflammatory cytokines including TNF-a, IFN-c, and IL-6 [19].
Interestingly we found minocycline significantly reduced the
number of pro-inflammatory monocytes, but did not affect the
number of classical CD14+CD162 monocytes. This may have
resulted from suppressed activation and maturation of monocytes,
down-regulation of CD16 in vivo, and/or decreased turnover and
trafficking of this subset of myeloid cells from the bone marrow.
In addition to its anti-inflammatory effects, minocycline inhibits
the growth of a wide variety of Gram-negative and Gram-positive
bacteria. Following oral administration, concentrations of mino-
cycline are highest in the bile and small intestine [39]. It is
therefore conceivable that in our SIV infection model of rapid
neuroAIDS, minocycline binds to and eliminates microbial
Table 2. Activation Markers on Monocyte Subsets.
Monocyte
Subset Day 27 (MFI) Terminal (MFI) P value
All Animals Untreated MN Treated
CD14+CD162
CD11b 11085 (5382) 37149 (17100) 10425 (1603) *
CD163 3178 (823) 8791 (2600) 3651 (1911) *
CCR2 478 (25) 1971 (649) 463 (170) ns
CD64 3443 (201) 5746 (842) 3793 (357) *
HLA-DR 3964 (950) 5480 (1747) 1754 (972) *
CD14+CD16+
CD11b 11099 (5261) 37560 (16295) 10171 (1184) ***
CD163 4156 (1047) 9140 (2381) 3728 (1754) *
CCR2 182 (58) 1172 (306) 303 (109) ns
CD64 1209 (162) 2175 (419) 1435 (96) *
HLA-DR 8060 (1875) 13160 (3689) 4145 (2456) *
CD14
loCD16+
CD11b 2715 (1131) 6807 (2751) 1822 (483) *
CD163 1344 (340) 3328 (572) 1214 (642) *
CCR2 27 (92) 360 (115) 113 (25) ns
CD64 390 (20) 763 (206) 434 (179) ns
HLA-DR 6010 (1408) 9247 (3465) 1227 (186) *
Note.-Means are the median fluorescence intensity, MFI, and the SEM is in
brackets.
MFI were calculated by subtracting the MFI of the appropriate isotype controls.
P values were calculated by comparing terminal MFI values for untreated and
minocycline treated animals using a Mann-Whitney U test (p,0.05*,
p,0.001***). MN=minocycline.
doi:10.1371/journal.pone.0018688.t002
Figure 1. Minocycline reduces expansion of activated monocytes. Flow cytometric analysis of CD14+CD162, CD14+CD16+, and
CD14
loCD16+ monocyte populations. Using flow cytometric analyses, monocytes were first selected based on size and granularity (FSC vs. SSC). From
this gate, HLA-DR+ CD14+ monocytes were selected. A small population of CD14-negative, HLA-DR-negative cells, likely representing lymphocytes or
dendritic cells, were excluded. We note that all monocytes are HLA-DR+ based on FSC vs. SSC and that the number of HLA-DR+ and absolute number
of monocytes are equivalent. From the CD14+ HLA-DR+ gate monocyte subsets were fractionated based on CD14 and CD16 expression (A).
Comparisons were made between SIV-infected, CD8+ T lymphocyte depleted animals with (filled symbols) and without (open symbols) minocyline
treatment. Minocycline treatment was initiated at day 28 post-infection (start date is marked by a solid vertical line). The absolute number of
CD14+CD162 monocytes was comparable between groups throughout the course of the study (B). In contrast, numbers of CD14+CD16+ (C) and
CD14
loCD16+ (D) monocytes were significantly higher in untreated animals at all points compared to minocycline treated animals. Data points
represent the mean 6 standard error of the mean (n=7 animals per group until 6 weeks pi when two untreated animals were time-sacrificed).
P values were calculated using a Mann-Whitney U test (p,0.05*, p,0.01**).
doi:10.1371/journal.pone.0018688.g001
Neuronal Protection by Minocycline
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inhibited expansion of highly activated CD16+ monocytes. In this
study, we assayed for LPS in plasma, but did not find significant
differences in levels of LPS between the treatment groups. This
does not rule out that minocycline might directly effect the
response of monocytes in vivo to translocated bacterial products.
Decreased expression and therefore potentially crosslinking of Fcc
receptors (CD16 and CD64) by antibody opsonized microbes in
minocycline treated monocytes could have resulted in decreased
transcription of inflammatory genes [40]. Minocycline treatment
has also been shown to strongly chelate iron, which is an essential
nutrient required by bacteria to survive and multiply [41].
Recent studies by Szeto et al. [42] indicate that by suppressing
lymphocyte activation, minocycline treatment reduces HIV
replication in CD4+ T lymphocytes. We observed a similar effect
in CD14+ monocytes in vitro, where reduction of viral replication
was directly related to the extent of CD16+ expression. It is
important to note that the concentrations of minocycline that we
used in vitro are physiologically similar to those found in humans
with minocycline treatment [35], [43]. These results indicate that
the antiviral effects of minocycline are linked to its ability to reduce
activation of monocytes and their permissiveness to viral infection.
CD14+CD16+ and CD14
loCD16+ monocytes are considered to
be at an advanced stage of maturation, and it has been proposed
that these cells are preferentially infected and harbor viral particles
long-term [16,17,44]. Current evidence suggests that restriction of
viral replication in less mature CD14+CD162 monocytes is
mediated by differentiation-dependent cofactors such as apolipo-
protein B mRNA-editing enzyme 3G (APOBEC3G) and APO-
BEC3A [45]. Upon CD16-mediated activation, the transcriptional
activators NF-kb and C/EBPb, which are essential factors for viral
replication in monocytes, are also induced [46]. Based on the
results from our study, it is conceivable that minocycline treated
monocytes display a restriction to SIV replication similar to that of
classically activated CD14+CD162 monocytes.
Despite the reported beneficial effects of minocycline in several
animal models of CNS disease, including ALS [47–49] a recent
clinical trial with ALS patients found patients deteriorated
significantly faster than the placebo control group [50]. These
results underscore that caution and more studies are required
before additional clinical work with minocycline. In addition, this
study underscores the importance of understanding differences
between animal models of disease and disease. Our data support
the notion that inhibition of monocyte/macrophage activation,
and possibly viral infection, correlates with neuronal protection
assessed by MRS. Our results suggest that minocycline may be
beneficial as an adjunctive therapy, to antiretroviral therapies, that
are less effective in crossing the BBB. This data was found using an
SIV model of CNS neuroAIDS, which might more accurately
mirror CNS pathology, than mouse models of ALS mirror the
human disease.
We report here that suppression of chronic immune activation
with minocycline treatment results in the reduced expansion of
highly activated and potentially infected pro-inflammatory mono-
cytes. Decreased expression of receptors such as CD11b, CD16,
and CCR2 critical for trafficking of monocytes into the brain
demonstrates that minocycline prevented the recruitment of these
highly invasive cells into the CNS.
Materials and Methods
Ethical Treatment of Animals
These studies were performed with the approval of the
Massachusetts General Hospital Subcommittee on Research and
Animal Care and the Institutional Animal Care and Use
Committee of Harvard University. Animals were housed accord-
ing to the standards of the American Association for Accreditation
of Laboratory Animal Care. Treatment of animals was in
accordance with the Guide for the Care and Use of Laboratory
Animals of the Institute of Laboratory Animal Resources.
Animals, SIV infection, CD8+ T lymphocyte depletion,
and Minocycline treatment
The cohort of animals used in this study was reported in a
recent publication of the effects of minocycline on CNS neural
Figure 2. Linear regression analyses reveal significant relationships between circulating pro-inflammatory monocytes and NAA/Cr.
Regression analyses were performed between the absolute numbers of each monocyte subset and the percent change in neuronal metabolite values
(NAA/Cr) in the frontal cortex relative to pre-infection levels for all animals from 28 days pi until necropsy. Minocycline treated and non-treated
animals were examined at 4 time-points except for the two animals that were time-sacrificed at 6 weeks pi, have three time-points. We found a
significant inverse relationship between both CD14+CD16+ (B;r
2=0.59, p=0.0004) and CD14
loCD16+ (C;r
2=0.45, p=0.04) monocytes and
decreased NAA/Cr, while no relationship between CD14+CD162 monocytes and NAA/Cr levels were observed (A;r
2=0.30, p=0.3776).
doi:10.1371/journal.pone.0018688.g002
Figure 3. Reduced CD68+, MAC387+, and SIV p28+ produc-
tively infected cells in lymph nodes with minocycline treat-
ment. Immunohistochemistry was performed to compare CD68+
resident macrophages, newly infiltrating MAC387+ monocytes/macro-
phages, and SIV-infected cells in the axillary lymph node from untreated
and minocycline treated animals. A reduced number of resident CD68+
macrophages (A–B) and newly infiltrating MAC387+ monocytes/
macrophages (C–D) in an axillary lymph node of minocycline treated
animals (B, D) and an untreated controls (A, C). In addition, there was a
significantly higher number of productively infected SIV p28+ cells in
the lymph node of untreated animals (E) compared to minocycline
treated animals (F). All scale bars are 50 mm.
doi:10.1371/journal.pone.0018688.g003
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minocycline treated animals were also included in the experiments
presented here for a total of n=14 animals. In the current
manuscript, we report the effects of minocycline on monocytes
from animals in this cohort, and perform correlations of monocyte
numbers vs. n-acetylaspartate/creatine (NAA/Cr), a marker of
neuronal injury. Fourteen rhesus macaques (Macaca mulatta) were
intravenously inoculated with SIVmac251 (20 ng SIV p27; a
generous gift from Dr. Ronald Desrosiers, NERPC) as previously
described [32]. CD8+ T lymphocyte depletion was achieved using
cM-T807, an anti-CD8+ antibody that was administered subcu-
taneously (10 mg/kg) on day 6 post infection (pi) and intrave-
nously (5 mg/kg) on days 8 and 12 pi [31,51,52]. Minocycline was
orally administered twice daily (2 mg/kg) to seven animals
beginning four weeks pi and continuing throughout the study
[32]. Macaques were sacrificed upon development of AIDS or at a
predetermined timed sacrifice following four weeks of minocycline
treatment.
Viral load, MRI and MRS
Plasma SIV RNA was quantified using real-time PCR as
previously described [52]. NAA/Cr measured values using MRI
and
1H magnetic resonance spectroscopy (MRS) were recently
published [32]. Here we correlate the NAA/Cr ratios in different
brain regions with monocyte activation and the expansion of
subpopulations.
Flow cytometry studies of monocytes
Peripheral blood was drawn on days 27, 6, 8, and 12 pi, and
weekly thereafter. Complete blood counts were obtained using a
CBC Hematology Analyzer (Hema-True, HESKA). Flow cyto-
metric analyses were performed with 100 ml samples of blood as
previously described [10]. Fluorochrome-conjugated primary
antibodies including anti-CD3-FITC (SP34-2), anti-CD4-FITC
(L200), anti-CD14-FITC (M5E2), anti-CD16-PE (3G8), anti-
HLA-DR-PerCPCy5.5 (G46-6), and isotype control anti-IgG1,
k-FITC (MOPC-21) all from BD Pharmingen, anti-CD64-FITC
(22) and anti-CD163-FITC (Mac2-48) from Trillium Diagnostics,
anti-CD8-PE (DK25; Dako), and anti-CD11b-APC (M1/
70.15.11.5; Miltenyi Biotec) were used. Samples were fixed in
PBS containing 2% formaldehyde, acquired on a FACSAria cell
sorter (Becton-Dickinson) and analyzed with Tree Star Flow Jo
version 8.7. Monocytes are first selected based on size and
granularity (FSC vs. SSC). From this gate, HLA-DR+ CD14+
monocytes were selected. We note all monocytes analyzed by FSC
vs. SSC are HLA-DR+. The absolute number of peripheral blood
monocytes was calculated by multiplying the total white blood cell
count by the total percentage of each monocyte subset population
as determined by flow cytometric analysis.
Immunohistochemistry
Axillary lymph nodes were collected in 10% neutral buffered
formalin, embedded in paraffin, and sectioned at 5 mm. Tissues
were deparafinized, rehydrated and incubated with blocking
reagents. Newly infiltrating monocyte/macrophages were identi-
fied by the expression of myeloid/histiocyte antigen MAC387
(MAC387; Dako) [53]. Mature resident monocyte/macrophage
and microglia were assessed using anti-CD68 (KP1; Dako) [54].
Cells that were productively SIV infected were studied using anti-
SIV-p28 (MX-0322; Microbix Biosystems) [55]. For quantifica-
tion, at least 3 non-serial axillary lymph node sections from each of
the fourteen macaques were stained for each marker. The number
of MAC387+, CD68+, and p28+ cells was counted from 4
arbitrary fields, and the data are expressed as the number of
Figure 4. Minocycline reduces the number of CD68+, MAC387+,
and p28+ cells in axillary lymph node. Quantitative analysis of
CD68+ revealed significantly fewer CD68+ cells in the axillary lymph
node of animals that received minocycline as compared to untreated
controls (A; p=0.0023); fewer numbers of newly infiltrating MAC387+
monocytes/macrophages (B; p=0.0033); and a decreased number of
productively SIV infected p28+ cells (C; p=0.0070). Numbers are
representative of the means from a minimum of twelve fields calculated
to represent a single data point for each animal. Horizontal bars
indicate group mean values and error bars indicate the standard error
of the mean. P values were determined using a Mann-Whitney U test.
doi:10.1371/journal.pone.0018688.g004
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2). Sections were
visualized with a Zeiss Axio Imager M1 microscope (Carl Zeiss
MicroImaging, Inc.) using a Plan-Apochromat 620/0.8 Korr
objective and analyzed using Adobe Photoshop v4 software.
In vitro infection and minocycline treatment
Peripheral blood mononuclear cells (PBMC) were prepared
from EDTA-coagulated blood obtained from healthy animals by
Ficoll density gradient separation. CD14+ monocytes were
isolated using CD14 MACS microbeads (Miltenyi Biotec). Isolated
CD14+ monocytes (.95% purity) were adjusted to a final
concentration of 5610
5 cells/mL in RPMI 1640 supplemented
with 11 g/L sodium pyruvate, 10% fetal bovine serum (Atlas
Biologicals), and 10 ng/mL M-CSF (Peprotech Inc). Using M-
CSF all monocytes in vitro were CD14+CD16+ prior to
minocycline treatment. Monocyte/macrophages were infected
with a highly macrophage tropic clone SIV316STOP virus (30 ng
of SIV p27; a generous gift from Dr. Ronald Desrosiers, NERPC)
at 37uC for 24 hours, then washed with PBS containing 2% FBS
to remove excess virus. Cells were cultured for 24 or 72 hours with
10 mM and 20 mM minocycline (Sigma Aldrich). Myeloid markers
were assessed by flow cytometry using anti-CD14-Pacific Blue (BD
Pharmingen; M5E2), anti-CD16-PE, anti-HLA-DR-PerCpCy5.5,
and anti-CD163-FITC antibodies. Viability of cells was deter-
mined using a LIVE/DEAD Fixable Dead Stain Kit (Invitrogen).
Viral replication in conditioned media was quantified by SIV p27
ELISA (Advanced BioScience Laboratories, Inc).
IL-6 and TNF induction by monocytes in vitro
CD14+ monocytes were isolated and cultured as described in
the previous section at a concentration of 1610
6 cells/mL for
16 hours in non-adherent conditions at 37uC. Monocyte/macro-
phages were then incubated for 3 hours at 37uC with or without
10 ng/mL or 100 ng/mL LPS (Sigma Aldrich), and 10 mg/mL
brefeldin A (Sigma Aldrich) for intracellular detection of cytokines.
After stimulation, cells were fixed and permeabilized with BD
Cytofix/Cytoperm
TM buffer (BD Biosciences) for 20 minutes at
4uC. Cells were washed and incubated with anti-CD16-PeCy7
(3G8) anti-IL-6-PE (MP5-20F3), anti-TNF-APC (MAb11), anti-
IgG1, k-APC (MOPC-21), and anti-IgG2a, k -PE (R35–95) all
from BD Pharmingen, anti-HLA-DR ECD (Immu-357; Beckman
Coulter), and anti-CD14-Pacific Blue antibodies for 30 minutes at
room temperature. Viability of cells was determined using a
LIVE/DEAD Fixable Dead Stain Kit and dead cells were
excluded. Data are expressed as the percent of total monocytes
producing IL-6 or TNF.
Statistical methods
We have previously described kinetics of NAA/Cr over time in
different brain regions of minocycline treated versus non-treated
animals [32]. Here we used a least-squares means model to identify
correlations between our previously determined NAA/Cr in
different brain regions and the absolute number of different
monocyte subsets. This method allows for the correlation of data
points that are not independent of one another, such as repeated
measurements of NAA/Cr or monocytes from the same animal.
Cross termsbetween animalsand monocyteswereperformedwhere
a significant cross term indicated that at least one animal’s slope
((NAA/Cr) / absolute monocytes) was contrary to a randomly
chosen reference animal. If such significance existed, the statistic
wasconsideredinvalid.StatisticalanalysiswasperformedusingJMP
7.0 (SAS, Cary, NC). Mann-Whitney U tests were used for all other
statistical analyses and performed using Prism version 5.0b
(GraphPad Software, Inc., San Diego, CA) software.
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Figure 5. Reduction of CD16 expression and viral replication in CD14+ monocytes during in vitro minocycline treatment. CD14+
monocytes were infected with SIVmac316STOP virus and cultured with M-CSF in the presence or absence of minocycline for 24 and 72 hours. With
M-CSF treatment, all monocytes expressed CD14 and CD16 prior to minocycline treatment. By flow cytometry, monocytes were first gated based on
size (FSC) and granularity (SSC). From this gate HLA-DR+ CD14+ monocytes were selected (A) and CD16 expression on these cells between treatment
groups was compared. Histograms represent the median fluorescence intensity (MFI) of CD16 from one representative experiment out of three (B).
Averages of MFI 6 standard error of the mean in a given treatment group are indicated in the upper left hand corner of the graphs. CD16 expression
was significantly higher on untreated than 20 mM minocycline treated monocytes at 48 hours pi (p=0.021). Untreated monocytes had significantly
higher CD16 expression than both 10 mM and 20 mM treated cells at 96 hours pi (p=0.001). After 96 hours of infection, SIV-p27 was reduced with
minocycline treatment (C), with significant differences between control and 20 mM minocycline (p=0.039). Studies presented here are the results of
n=3 three independent experiments with n=3 animals per experiment performed in triplicate wells. P values were determined using a Mann-
Whitney U test.
doi:10.1371/journal.pone.0018688.g005
Figure 6. Minocycline treatment inhibits induction of IL-6 by
CD14+ monocytes in vitro. CD14+ monocytes were cultured in non-
adherent conditions with M-CSF and in the presence or absence of
minocycline for 16 hours. IL-6 was induced by LPS in the presence of
brefeldin A for 3 hours. The percentage of monocytes producing IL-6 was
significantly lower with 10 mM( p=0.04) and 20 mM( p=0.009) minocy-
cline than in untreated cells. With 10 ng/mL LPS, the percent of IL-6
producing monocytes was significantly reduced with 20 mM as compared
to 10 mM minocycline treatment (p=0.016). With 100 ng/mL LPS
stimulation, minocycline treatment at both 10 mM( p=0.058)and20mM
(p=0.03) doses significantly inhibited IL-6 cytokine secretion in CD14+
monocytes. Data presented represent the results of two independent
experiments with n=3 animals per experiment performed in triplicate
wells. P values were determined using a Mann-Whitney U test.
doi:10.1371/journal.pone.0018688.g006
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